Evidence map›Paper›PMID 39337500›Full record

ArticleInternational journal of molecular sciences2024

A New Approach for CRISPR/Cas9 Editing and Selection of Pathogen-Resistant Plant Cells of Wine Grape cv. 'Merlot'.

Anastasia Fizikova, Zhanneta Tukhuzheva, Lada Zhokhova, Varvara Tvorogova, Ludmila Lutova

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. CRISPR-Based Editing of thePlants (Basel, Switzerland) · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anastasia FizikovaPlant Biology and Biotechnology Department, Sirius University of Science and Technology, Olympic Avenue 1, 354340 Sochi, Russia.ORCID 0000-0002-3568-9296
Zhanneta TukhuzhevaPlant Biology and Biotechnology Department, Sirius University of Science and Technology, Olympic Avenue 1, 354340 Sochi, Russia.ORCID 0000-0001-7864-9633
Lada ZhokhovaPlant Biology and Biotechnology Department, Sirius University of Science and Technology, Olympic Avenue 1, 354340 Sochi, Russia.
Varvara TvorogovaPlant Biology and Biotechnology Department, Sirius University of Science and Technology, Olympic Avenue 1, 354340 Sochi, Russia.
Ludmila LutovaPlant Biology and Biotechnology Department, Sirius University of Science and Technology, Olympic Avenue 1, 354340 Sochi, Russia.

Funding

Ministry of Science and Higher Education of Russian Federation Agreement 075-10-2021-093, Project [GNZH-RD-2008]
6 · The paper itself

Abstract

Grape is one of the most economically significant berry crops. Owing to the biological characteristics of grapes, such as the long juvenile period (5-8 years), high degree of genome heterozygosity, and the frequent occurrence of inbreeding depression, homozygosity during crossbreeding leads to loss of varietal characteristics and viability. CRISPR/Cas editing has become the tool of choice for improving elite technical grape varieties. This study provides the first evidence of a decrease in the total fraction of phenolic compounds and an increase in the concentration of peroxide compounds in grape callus cells upon the addition of chitosan to the culture medium. These previously unreported metabolic features of the grape response to chitosan have been described and used for the first time to increase the probability of selecting plant cells with

Indexed as

CRISPR-Cas SystemsGene EditingVitisChitosanDisease ResistancePhenolsPlant CellsPlant DiseasesPlant ProteinsWineChitosanPhenolsPlant ProteinsCRISPR/Cas9grape editingmildewplant biotechnologyplant resistance

Identifiers

PMID39337500
PMCPMC11432302

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.